✦ LIBER ✦

Pharmacokinetics and pharmacodynamics of dichloroacetate in patients with cirrhosis*1

✍ Scribed by SHANGRAW, R

Book ID: 111720485
Publisher: Nature Publishing Group
Year: 1999
Tongue: English
Weight: 153 KB
Volume: 66
Category: Article
ISSN: 0009-9236
DOI: 10.1053/cp.1999.v66.a101340

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Bioavailability, pharmacokinetics, and p

Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide in patients with cirrhosis

✍ Schwartz, Steven; Brater, D Craig; Pound, David; Green, Paula K; Kramer, William 📂 Article 📅 1993 🏛 Nature Publishing Group 🌐 English ⚖ 961 KB

The pharmacokinetics and pharmacodynamic

The pharmacokinetics and pharmacodynamics of perindopril in patients with hepatic cirrhosis.

✍ HH Tsai; KR Lees; CW Howden; JL Reid 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 829 KB

Pharmacodynamic and pharmacokinetic stud

Pharmacodynamic and pharmacokinetic study of propranolol in patients with cirrhosis and portal hypertension.

✍ P Cales; D Grasset; A Ravaud; C Meskens; M Blanc; JP Vinel; J Cotonat; JP Pascal 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 962 KB

Pharmacodynamics, Chiral Pharmacokinetic

Pharmacodynamics, Chiral Pharmacokinetics, and Pharmacokinetic-Pharmacodynamic Modeling of Fenoprofen in Patients With Diabetes Mellitus

✍ Poggi, Josiane Cristófani; Barissa, Giuliano Rodrigo; Donadi, Eduardo Antônio; F 📂 Article 📅 2006 🏛 Sage Publications 🌐 English ⚖ 90 KB

Buspirone pharmacokinetics in patients w

Buspirone pharmacokinetics in patients with cirrhosis.

✍ K Dalhoff; HE Poulsen; P Garred; M Placchi; RE Gammans; RF Mayol; M Pfeffer 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 468 KB

Pharmacokinetics of paroxetine in patien

Pharmacokinetics of paroxetine in patients with cirrhosis

✍ K. Dalhoff; T. P. Almdal; K. Bjerrum; S. Keiding; H. Mengel; J. Lund 📂 Article 📅 1991 🏛 Springer 🌐 English ⚖ 419 KB

In a 14-day multiple-dose study the pharmacokinetics of paroxetine was investigated in 12 patients with alcoholic cirrhosis and in 6 subjects without liver disease. The dose of 20-30 mg paroxetine daily was adjusted to the reduction in liver function, as assessed by the galactose elimination capacit